What post‑exposure prophylaxis and empiric treatment should be given to a 23‑year‑old female after potential STD exposure?

Post-Exposure STD Prophylaxis for 23-Year-Old Female

For a 23-year-old cisgender female after potential STD exposure, provide empiric prophylaxis with ceftriaxone 500 mg IM single dose for gonorrhea, doxycycline 100 mg PO twice daily for 7 days for chlamydia, and metronidazole 2 g PO single dose for trichomonas, along with emergency contraception if indicated. 1, 2

Key Clinical Decision Points

Standard Prophylaxis Regimen

The evidence-based approach for cisgender women differs significantly from the doxycycline post-exposure prophylaxis (doxy PEP) strategy:

• Bacterial STI coverage: Approximately 15% of sexual assault survivors acquire an STI, making prophylaxis essential 2
• Triple therapy approach:
  • Ceftriaxone for gonorrhea (single dose IM)
  • Doxycycline for chlamydia (7-day course, NOT the 200 mg single dose used in doxy PEP)
  • Metronidazole for trichomonas (particularly important for individuals with vaginas) 1, 2

Critical Caveat: Doxy PEP Does NOT Apply Here

The 2024 CDC doxy PEP guidelines specifically recommend doxycycline 200 mg post-exposure prophylaxis ONLY for men who have sex with men (MSM) and transgender women who have had a bacterial STI in the past 12 months 3. This patient does not meet these criteria for three reasons:

1. She is a cisgender female
2. The indication is different (potential exposure vs. ongoing prevention in high-risk individuals)
3. The evidence base for doxy PEP effectiveness comes exclusively from trials in MSM and transgender women populations 4, 5

Additional Prophylaxis Considerations

HIV Post-Exposure Prophylaxis (nPEP)

Assess HIV risk based on:

• Timing: Must initiate within 72 hours of exposure (sooner is better)
• Risk factors: Known HIV-positive source, high-prevalence area, receptive anal/vaginal intercourse with ejaculation, presence of bleeding/trauma 1, 6
• Regimen: 28-day course of antiretroviral therapy if indicated
• Baseline testing: HIV test before starting nPEP 1

Hepatitis B Prophylaxis

• Assess vaccination status
• Provide hepatitis B vaccination if not previously vaccinated 1, 2
• Consider hepatitis B immunoglobulin in high-risk scenarios with unvaccinated individuals

HPV Vaccination

• Recommend HPV vaccination series if not previously completed 1, 2

Testing and Follow-Up Protocol

Baseline Testing (at initial visit)

• Gonorrhea and chlamydia NAAT from all exposed sites (vaginal, rectal, pharyngeal)
• Syphilis serology
• HIV testing
• Hepatitis B and C serology
• Pregnancy test 1, 2

Follow-Up Schedule

• 1-2 weeks: Review initial test results, assess for symptoms
• 4-6 weeks: Repeat syphilis serology if initial negative
• 3 months: Repeat HIV, syphilis testing; assess for anogenital warts 1
• 6 months: Final HIV testing if initial negative 1

Common Pitfalls to Avoid

1. Do not use doxy PEP protocols for cisgender women: The single 200 mg dose is insufficient for treatment and not evidence-based for this population
2. Do not delay prophylaxis: Administer at the initial visit regardless of testing results 1, 2
3. Do not forget trichomonas coverage: This is specifically important for individuals with vaginas and often overlooked 2
4. Do not miss the 72-hour window for HIV nPEP: This is time-critical 1, 6
5. Do not provide prophylaxis alone: Must include emergency contraception assessment, safety planning, and mental health screening 2, 7

Strength of Evidence Discussion

The recommendation for empiric triple antibiotic prophylaxis in sexual assault survivors comes from established CDC guidelines 1 and recent expert consensus 2. While the doxy PEP literature is robust and recent (2024 guidelines with strong RCT evidence showing >70% reduction in syphilis and chlamydia) 3, 4, this evidence explicitly excludes cisgender women from the recommended population. The trial data demonstrating doxy PEP efficacy involved only MSM and transgender women 4, 5, making extrapolation to cisgender women inappropriate without supporting evidence.